171 related articles for article (PubMed ID: 10348681)
1. Control of HIV despite the discontinuation of antiretroviral therapy.
Lisziewicz J; Rosenberg E; Lieberman J; Jessen H; Lopalco L; Siliciano R; Walker B; Lori F
N Engl J Med; 1999 May; 340(21):1683-4. PubMed ID: 10348681
[No Abstract] [Full Text] [Related]
2. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.
Sankatsing SU; van Praag RM; van Rij RP; Rientsma R; Jurriaans S; Lange JM; Prins JM; Schuitemaker H
Antivir Ther; 2003 Apr; 8(2):137-42. PubMed ID: 12741626
[TBL] [Abstract][Full Text] [Related]
3. Effect of antiretroviral therapy on plasma HIV RNA.
Saag MS
J Biol Regul Homeost Agents; 1995; 9(3):105-6. PubMed ID: 8782017
[No Abstract] [Full Text] [Related]
4. Immune control of HIV-1 after early treatment of acute infection.
Rosenberg ES; Altfeld M; Poon SH; Phillips MN; Wilkes BM; Eldridge RL; Robbins GK; D'Aquila RT; Goulder PJ; Walker BD
Nature; 2000 Sep; 407(6803):523-6. PubMed ID: 11029005
[TBL] [Abstract][Full Text] [Related]
5. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
[TBL] [Abstract][Full Text] [Related]
6. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.
Abbas UL; Mellors JW
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13377-8. PubMed ID: 12370421
[No Abstract] [Full Text] [Related]
7. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
Marcello A; Giacca M
Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
[No Abstract] [Full Text] [Related]
8. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
Tebas P; Henry K; Mondy K; Deeks S; Valdez H; Cohen C; Powderly WG
J Infect Dis; 2002 Sep; 186(6):851-4. PubMed ID: 12198623
[TBL] [Abstract][Full Text] [Related]
9. HIV therapeutics: points from the recent literature.
Laurence J
AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448
[No Abstract] [Full Text] [Related]
10. [New biological monitoring of HIV infection].
Morand-Joubert L
Rev Prat; 1998 Mar; 48(5):472-7. PubMed ID: 9781107
[No Abstract] [Full Text] [Related]
11. CD8 T-cell response to antiretroviral therapy.
Stricker RB; Goldberg B
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jun; 15(2):176-7. PubMed ID: 9241121
[No Abstract] [Full Text] [Related]
12. Ongoing HIV dissemination during HAART.
Grossman Z; Polis M; Feinberg MB; Grossman Z; Levi I; Jankelevich S; Yarchoan R; Boon J; de Wolf F; Lange JM; Goudsmit J; Dimitrov DS; Paul WE
Nat Med; 1999 Oct; 5(10):1099-104. PubMed ID: 10502799
[No Abstract] [Full Text] [Related]
13. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
[TBL] [Abstract][Full Text] [Related]
14. HIV preferentially infects HIV-specific CD4+ T cells.
Douek DC; Brenchley JM; Betts MR; Ambrozak DR; Hill BJ; Okamoto Y; Casazza JP; Kuruppu J; Kunstman K; Wolinsky S; Grossman Z; Dybul M; Oxenius A; Price DA; Connors M; Koup RA
Nature; 2002 May; 417(6884):95-8. PubMed ID: 11986671
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 and HAART: a time to cure, a time to kill.
Saag MS; Kilby JM
Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490
[No Abstract] [Full Text] [Related]
16. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
[TBL] [Abstract][Full Text] [Related]
17. Highly active antiretroviral therapy leads to a significant but delayed increase of CD45RA+ T-helper cells.
Degen O; Stellbrink HJ; Lauer J; van Lunzen J
AIDS; 1998 Sep; 12(13):1715-6. PubMed ID: 9764793
[No Abstract] [Full Text] [Related]
18. HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.
Tamburrini E; Ravizza M; Floridia M; Tibaldi C; Alberico S; Anzidei G; Maccabruni A; Meloni A; Antoni AD; Mori F; Dalzero S; Conservan V; Pinnetti C; Ferrazzi E;
Antivir Ther; 2008; 13(4):519-27. PubMed ID: 18672530
[TBL] [Abstract][Full Text] [Related]
19. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
